Patients fulfilling any of the following criteria are not eligible for inclusion in this study. No
additional exclusions may be applied by the investigator, in order to ensure that the study
population will be representative of all eligible patients.
1. Patients whose baseline serum IgE levels1 or body weight are outside the limits of the
locally approved omalizumab dosing table.
1See Section 22.214.171.124 for definition of baseline serum IgE and refer to relevant locally
approved omalizumab dosing table in the QGE031B2201 study manual.
2. Who have smoked or inhaled tobacco products within the 6 month period prior to Visit 1,
or who have a smoking history of greater than 10 pack years (e.g.10 pack years = 1 pack
/day x 10 yrs., or ½ pack/day x 20 yrs).
3. Who have had an asthma attack/exacerbation requiring a short burst of systemic
corticosteroids for at least 3 days within 6 weeks prior to Visit 1.
4. If patients experience an asthma attack/exacerbation requiring a short burst of systemic
corticosteroids during screening and run-in they may be re screened 6 weeks after
recovery from the exacerbation.
5. Who have had a respiratory tract infection or asthma worsening within 4 weeks prior to
6. If patients experience a respiratory tract infection or asthma worsening during screening
and run-in they may be re screened 4 weeks after recovery from their respiratory tract
7. Patients with a history of life-threatening asthma within the previous 10 years, including a
history of significant hypercarbia (pCO2>45mmHg), prior intubation (endotracheal and
NIPPV), respiratory arrest, or seizures as a result of asthma.
8. Who have a history of generalized urticaria or who have an acute urticaria episode at time
of screening or during run-in. If patients experience an acute urticaria episode at screening
or run-in, they may be re-screened once the urticaria has resolved.
9. Patients with evidence upon visual inspection (laboratory culture is not required) of
clinically significant oropharyngeal candidiasis during screening and run-in, with or
without treatment. Patients may be re screened once their candidiasis has been treated and
10. Patients with any chronic conditions affecting the upper respiratory tract (e.g. chronic
sinusitis) which in the opinion of the investigator may interfere with the study evaluation
or optimal participation in the study.
11. Patients with a history of chronic lung diseases other than asthma, including (but not
limited to) chronic obstructive pulmonary disease, bronchiectasis (non-clinically
significant bronchiectasis may be allowed provided recent (within 3 months prior to Visit
1) CT scan proof is available), sarcoidosis, interstitial lung disease, cystic fibrosis, and
12. Patients with aspirin or other nonsteroidal anti-inflammatory drug related asthma.
13. Patients with elevated serum IgE levels for reasons other than atopic conditions (e.g.,
parasitic infections, hyperimmunoglobulin E syndrome, allergic bronchopulmonary
14. Patients with uncontrolled diabetes Type I or uncontrolled diabetes Type II having an
HbA1C test result ≥ 8% at Visit 101.
15. Patients who have a clinically significant laboratory abnormality that is not compatible
with the natural history of atopic asthma at run-in Visit 101, in the judgment of the
16. Patients who, either in the judgment of the investigator have a clinically significant
condition such as (but not limited to) unstable ischemic heart disease, NYHA Class III/IV
left ventricular failure arrhythmia, uncontrolled hypertension, cerebrovascular disease,
neurodegenerative diseases, or other neurological disease, uncontrolled hypo- and
hyperthyroidism and other autoimmune diseases, hypokalemia, hyperadrenergic state, or
ophthalmologic disorder or patients with a medical condition that might compromise
patient safety or compliance, interfere with evaluation, or preclude completion of the
17. Patients with a history of myocardial infarction within the previous 12 months.
18. With a history or current treatment for hepatic disease including but not limited to acute or
chronic hepatitis, cirrhosis or hepatic failure or an AST/ALT or INR of more than 1.5x
ULN at run-in Visit 101.
19. With history of severe renal failure or creatinine level above 1.5x ULN at run-in Visit 101.
20. History of malignancy of any organ system (other than localized basal cell carcinoma of
the skin), treated or untreated, within the past 5 years, regardless of whether there is
evidence of local recurrence or metastases.
21. Patients with a history of long QT syndrome or whose QTc measured at run-in (either
Visit 101 or Visit 102) (Fridericia method) is prolonged (>450 ms for males and females)
and confirmed by a central assessor. (These patients should not be re-screened).
22. Patients who have a clinically significant ECG abnormality at run-in Visit 101.
23. Patients who have a clinically significant ECG abnormality prior to randomization (Visit
24. Patients with a stool examination positive for ova or parasites (at run-in); re-screening
may be considered if a repeat stool examination is negative following treatment.
25. With a history of immunodeficiency diseases or active hepatitis B or C.
26. Patients with a known hypersensitivity against any constituents of the study drugs or to
murine, chimeric, or human antibodies.
27. Patients who do not maintain regular day/night, waking/sleeping cycles.
28. Patients who have not achieved acceptable spirometry results at Visit 101 in accordance
with ATS/ERS criteria for acceptability and repeatability.
29. Patients receiving any medications in the classes listed in (Table 5-2).
30. Patients receiving any Asthma related medications in the classes specified in (Table 5-3)
unless they undergo the required washout period prior to Visit 101 and follow the
adjustment to treatment program.
31. Patients receiving medications in the classes listed in (Table 5-4) should be excluded
unless the medication has been stabilized for the specified period and the stated conditions
have been met.
32. Patients receiving immunotherapy (desensitization) for allergies, unless maintenance dose
has been administered for at least 3 months prior to Visit 101, and is expected to remain
unchanged throughout the course of the study.
33. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 halflives
prior to Visit 1, whichever is longer.
34. Previous exposure to QGE031.
35. Patients unable or unwilling to receive sub-cutaneous injections.
36. History of alcohol or other substance abuse in the 12 months prior to Visit 1.
37. Patients with a known history of non-compliance to medication, or who were unable or
unwilling to complete a patient diary, or who are unable or unwilling to use Electronic
Peak Flow with e-diary device or perform spirometry measurements.
38. No person directly associated with the administration of the study is allowed to participate
as a study subject. No family member of the investigational study staff is allowed to
participate in this study.
39. Women of child-bearing potential, defined as all women physiologically capable of
becoming pregnant, unless they are using highly effective methods of contraception
during dosing and for 105 days (= 5 times the terminal half-life) of study medication.
Highly effective contraception methods include:
• Total abstinence (when this is in line with the preferred and usual lifestyle of the
subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation
methods) and withdrawal are not acceptable methods of contraception
• Female sterilization (have had surgical bilateral oophorectomy with or without
hysterectomy) or tubal ligation at least six weeks before taking study treatment. In
case of oophorectomy alone, only when the reproductive status of the woman has
been confirmed by follow up hormone level assessment
• Male sterilization (at least 6 m prior to screening). For female subjects on the study,
the vasectomized male partner should be the sole partner for that subject
• Combination of any two of the following (a+b or a+c or b+c)
a. Use of oral, injected or implanted hormonal methods of contraception or other
forms of hormonal contraception that have comparable efficacy (failure rate <1%),
for example hormone vaginal ring or transdermal hormone contraception.
b. Placement of an intrauterine device (IUD) or intrauterine system (IUS)
c. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or
cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository
In case of use of oral contraception women should have been stabile on the same pill
for a minimum of 3 months before taking study treatment.
Women are considered post-menopausal and not of child bearing potential if they have
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical
profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical
bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six
weeks ago. In the case of oophorectomy alone, only when the reproductive status of
the woman has been confirmed by follow up hormone level assessment is she
considered not of child bearing potential.
40. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female
after conception and until the termination of gestation, confirmed by a positive hCG